Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBI vs MRI in High-Risk Breast Cancer Screening
NCT05042687Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of technetium-99m sestamibi in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Diagnostic performance of Molecular Breast Imaging (MBI) to breast Magnetic Resonance Imaging (MRI) at 1 year. Started Dec 2021; status: recruiting.
02
Drugs
technetium-99m sestamibi
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05042687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042687.